- Home
- XOMA vs RAPT Comparison
XOMA vs RAPT Comparison
Compare XOMA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- RAPT
- Stock Information
- Founded
- XOMA 1981
- RAPT 2015
- Country
- XOMA United States
- RAPT United States
- Employees
- XOMA N/A
- RAPT N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- XOMA Health Care
- RAPT Health Care
- Exchange
- XOMA Nasdaq
- RAPT Nasdaq
- Market Cap
- XOMA 457.6M
- RAPT 498.4M
- IPO Year
- XOMA N/A
- RAPT 2019
- Fundamental
- Price
- XOMA $33.33
- RAPT $28.77
- Analyst Decision
- XOMA Strong Buy
- RAPT Strong Buy
- Analyst Count
- XOMA 2
- RAPT 9
- Target Price
- XOMA $69.50
- RAPT $56.78
- AVG Volume (30 Days)
- XOMA 43.0K
- RAPT 715.4K
- Earning Date
- XOMA 11-05-2025
- RAPT 11-06-2025
- Dividend Yield
- XOMA N/A
- RAPT N/A
- EPS Growth
- XOMA N/A
- RAPT N/A
- EPS
- XOMA N/A
- RAPT N/A
- Revenue
- XOMA $44,952,000.00
- RAPT N/A
- Revenue This Year
- XOMA $88.91
- RAPT N/A
- Revenue Next Year
- XOMA $13.80
- RAPT N/A
- P/E Ratio
- XOMA N/A
- RAPT N/A
- Revenue Growth
- XOMA 194.98
- RAPT N/A
- 52 Week Low
- XOMA $18.35
- RAPT $5.67
- 52 Week High
- XOMA $39.92
- RAPT $42.39
- Technical
- Relative Strength Index (RSI)
- XOMA 44.97
- RAPT 54.63
- Support Level
- XOMA $31.97
- RAPT $27.87
- Resistance Level
- XOMA $34.71
- RAPT $29.66
- Average True Range (ATR)
- XOMA 1.43
- RAPT 1.96
- MACD
- XOMA -0.09
- RAPT -0.60
- Stochastic Oscillator
- XOMA 44.06
- RAPT 12.80
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.